Table 7 Patient-level factors associated with receiving low-dose apixaban from the Veterans Health Administration, as compared to receiving full-dose, among those who met clinical criteria to receive full-dose apixaban for non-valvular atrial fibrillation. This table includes patients with only body mass suggesting a need for low-dose therapy (i.e., age < 80, serum creatinine < 1.5, and body mass ≤ 60 kg, n = 242)

 ≤ 69

17.9%

32.7%

REF

 70–74

17.9%

31.8%

1.56

(0.34, 7.71)

0.57

 75–79

64.3%

35.5%

3.31

(0.94, 14.33)

0.08

 Female

17.9%

9.8%

1.84

(0.43, 6.70)

0.37

 Male

82.1%

90.2%

REF

 White

82.1%

81.8%

REF

 Black

10.7%

10.7%

0.98

(0.19, 3.80)

0.98

 Other

7.1%

7.5%

0.91

(0.12, 4.47)

0.92

 Northeast

7.1%

15.0%

REF

 Midwest

14.3%

24.3%

1.22

(0.20, 10.09)

0.84

 West

28.6%

21.0%

2.43

(0.43, 19.88)

0.34

 South

50.0%

39.7%

1.34

(0.27, 10.13)

0.74

 < 50

28.6%

14.0%

2.87

(0.92, 8.64)

0.061

 50–59

71.4%

86.0%

REF

 Heart Failure

21.4%

20.1%

1.25

(0.29, 5.03)

0.76

 Hypertension

67.9%

62.1%

1.03

(0.29, 4.07)

0.97

 Vascular Disease

14.3%

22.4%

0.89

(0.22, 3.14)

0.87

 Diabetes

50.0%

41.1%

1.49

(0.49, 4.68)

0.48

 Prior Bleeding

0.0%

4.7%

0

NA

NA

 Stroke

7.1%

13.6%

0.21

(0.01, 1.40)

0.18

 <  1

67.9%

61.2%

REF

 1.0–1.29

7.1%

14.0%

0.68

(0.09, 3.04)

0.64

 1.3–1.49

10.7%

9.3%

0.79

(0.10, 4.16)

0.79

 0–2

14.3%

18.7%

REF

 3–4

35.7%

35.0%

1.83

(0.36, 11.34)

0.48

 ≥ 5

39.3%

41.6%

1.44

(0.21, 10.79)

0.71